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Glossary
Single nucleotide polymorphism (SNP): A single nucleotide
variation in a genetic sequence, meaning that the purine or
pyrimidine base of that nucleotide has been replaced by another purine or pyrimidine base, that occurs at a significant
frequency in the population.1
Polymorphism: The existence of many different DNA sequences at a locus, a specific location on a chromosome,
within the population.2
Allele: One member of a pair, or of a series, of genes on a specific locus that controls the same trait.3
DRD2 and DRD3 genetic codes: DNA that codes for dopamine receptors D2 and 03.4
Heterozygous deletion genotype: The individual has one
normal allele and has one allele with a deletion of one or
more base pairs.
Heterozygous A1/A2 genotype: The individual is heterozygous meaning that they express two different alleles of a
gene.
Homozygotes of an allele: The individual expresses two of
the same allele of a gene.
1. Single nucleotide polymorphism. (2011, October 10). Retrieved from
http://ghr.nlm.nlh.gov/glossary=singlenucleotidepolymorphism.
2. Genetic polymorphism. (2008, December 6). Retrieved from http://
www.biology-online.org/ dictionary/Genetic_polymorphism.
3. Allele. (2008, June 17). Retrieved from http://www.biology-onllne.org/
dictionary/Allele.
4. S. Nanko, R. Fukuda, M. Hattori, et al. (1994). Linkage studies between
affective disorder and dopamine D2, DJ, and 04 receptor gene loci in four
Japanese pedigrees. Psychiatry Research, 52:149-157.

Abstract
Pharmacogenomics is a growing area of pharmacy that has
the potential to improve individualization of medication
choices, dosing and predictability of side effects. Clozapine
and risperidone are atypical antipsychotics whose metabolism, efficacy and side effects are influenced by single nucleotide polymorphisms (SNPs) in a patient's genetic makeup. It
has been shown that a polymorphism in the D3 dopamine receptor is ass©ciated with an increased risk in developing
tardive dyskinesia as an adverse event while taking risperidone. Also, there is evidence that a patient with a homogenous
C genotype in the gene coding for the 5-HTzc receptor has a
higher risk of weight gain from taking clozapine than a patient
with a heterogeneous T genotype of that same gene. There are
many other SNPs that have been, or are currently being, investigated with regards to the efficacy and side effects of clozapine
and risperidone. However, more studies with longer durations
and larger sample sizes are needed to determine the actual
clinical significance of these genetic variants. In the future,
pharmacis·ts have the opportunity to become leaders in the
area of pharmacogenomics to help apply this information to
optimize patient outcomes and minimize adverse events.
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Introduction
Patient responses to medications, particularly antipsychotics,
can be extremely variable. This variability partially can be
attributed to the genetic differences between patients. The
study of these genetic differences and responses to medications is known as pharmacogenomics. The goal of pharmacogenomics is to allow for patient specific medication therapy
through the application of genetic information related to
drug absorption, distribution, metabolism and excretion, as
well as drug response. SNPs may be utilized as biomarkers to
determine drug metabolism and response. A thorough understanding of the consequences of discrete changes in an
individual's DNA allows for evaluation of the efficacy and
potential toxicity of antipsychotic medications.
Mental health medications, or antipsychotics, are used to
treat the symptoms of a variety of conditions including
schizophrenia, depression, bipolar disorder, anxiety disorders, and attention deficit-hyperactivity disorder (ADHD).
Some of these medications have been available since the mid
-19 5 Os, and are classified as conventional, typical or first
generation (FGA) antipsychotics. In the 1990s, new antipsychotic medications were developed. These new medications
are classified as "atypical" antipsychotics or second generation antipsychotics (SGA).1

Clozapine and Risperidone
Clozapine is an SGA used to treat the symptoms of schizophrenia in patients who do not respond to other medications
or who are suicidal.2 It is commercially available in tablet
form as well as an oral disintegrating tablet (ODT) both of
which are available in multiple strengths.
Clozapine may cause adverse events including weight gain4,
drowsiness, dizziness, restlessness and headache, among
others. It also has anticholinergic properties. Serious adverse
events include uncontrollable shaking of the extremities, seizures, fainting, confusion, severe muscle stiffness, changes in
behavior, fever and flu-like symptoms.2 Clozapine also has
five black box warnings concerning the potential for agranulocytosis, seizures, myocarditis, orthostatic hypotension and
increased risk of death.3
Risperidone, also an SGA, is indicated for the treatment of
schizophrenia in adults and adolescents, as well as the treatment of acute bipolar disorder in adults, children and adolescents. Risperidone is available as a tablet, an ODT and an oral
solution. Risperidone contains a black box warning for increased incidence of cerebrovascular adverse events and
mortality in elderly dementia patients. Other serious adverse
events include tardive dyskinesia (TD), extrapyramidal
symptoms (EPS) and weight gain.s
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Clozapine and risperidone are dibenzodiazepine antipsychotics. Clozapine blocks the serotonin (SHT2), alpha-adrenergic,
histamine Hi and cholinergic receptors. It also acts as a weak
antagonist to the D1, D2, 03 and Ds dopamine receptor subtypes, however it shows high binding affinity for
04 dopamine receptors.3 Likewise, risperidone is a strong
antagonist of the serotonin S-HT2 receptors, the dopamine D2
and 03 receptors, and the alpha-1 adrenergic receptors.6 It
has been noted that CYP2D6 is primarily responsible for metabolizing risperidone.4
The Effects of Genetic Variation on C/ozapine Treatment
Clozapine binds with the highest affinity to the 04 dopamine
receptor. It has been hypothesized that the 04 dopamine receptor genotype has a role in determining the effect of
clozapine. The 04 dopamine receptor (DRD4) gene codes for
the 04 dopamine receptor. This gene is being studied because
it is hypothesized that the longer the length of the repeat of
the DR04 allele, the lower the binding affinity will be for
clozapine. Several studies have been performed regarding
this gene, and all studies yielded conflicting results. With
more information on this particular gene and its coding,
health care professionals will be able to determine if clozapine is an appropriate treatment for a patient based on how
many repeats ofa patient's particular allele are present. 4

Clozapine is metabolized by CYP1A2, CYP206 and CYP3A4
enzymes. Various drugs can inhibit the function of these enzymes causing an increase in the plasma concentration of
clozapine. If inhibitors of the aforementioned enzymes are
given along with clozapine, a reduction in the clozapine dose
would be necessary in order to avoid adverse events due to
increased plasma clozapine levels. Conversely, there are several drugs which act as inducers of the CYP1A2, CYP206 and
CYP3A4 enzymes. If a patient is using any of these inducers,
the dose of clozapine may need to be increased in order to
achieve therapeutic concentrations. Genes code for the expression of these CYP enzymes, and individuals can express
different amounts of CYP enzymes depending on each individual's genetic code. For instance, an individual can either
be heterozygous or homozygous for a specific CYP enzyme.
Therefore, if the homozygous individual is taking a CYP3A4
inducer along with clozapine, that person is more likely to
experience a higher clearance of clozapine than the heterozygous patient. The homozygous person would require an even
greater dose of clozapine in order for the drug to have any
therapeutic benefits. Therefore, by analyzing an individual's
genetic code, health care professionals can adjust the dose of
clozapine to achieve therapeutic plasma levels and avoid toxicity.4,6,7
Clozapine is said to antagonize S-HT2A, S-HT2c, and S-HT6
receptors. Therefore, genes that encode these receptors may
play a significant role in predicting clozapine response. An
amino acid change has been identified as a result of the SNP
rs6313 (T102C). This variant S-HT2A receptor protein shows
an association with poor response to clozapine; this association was confirmed through meta-analysis of several studies.4. s
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Clozapine can cause significant weight gain as an adverse
event. Several studies analyzing the relationship between the
SNP rs3813929 (C-759T) of the S-HT2c receptor and weight
gain have been conducted. A review of 10 studies showed
that the C allele, specifically a homogenous C genotype, was
associated with more weight gain than the T allele, specifically a heterogeneous T genotype. A meta-analysis of eight
studies showed that the T allele is protective against antipsychotic therapy weight gain, and the C allele was found to be
related to a two-fold increased risk for weight gain. The C
allele is more common than the T allele, suggesting that genetic testing of a patient can indicate the potential for significant weight gain as an adverse event of clozapine therapy.4
The Effects of Genetic Variation on Risperidone Treatment
The most commonly investigated SNPs are found in the 0 2
dopamine receptors and 03 dopamine receptor genetic
codes. The SNP rs1799732 (-141C Ins/Del) of the D2dopamine receptor, which results in an altered amino acid sequence of the receptor protein, has had significant associations with negative response symptoms and adverse events
such as TD. A 2002 study, which also investigated the SNP
rs1800497 TaqlA, determined a significant improvement
(40 percent) in the response to risperidone in patients with
both a heterozygous deletion genotype and a heterozygous
Al/ A2 genotype, however the results of this study were limited due to a small sample population.9 A similar study, with
a larger sample population, conducted in 2011 detected an
improvement in the Brief Psychiatric Rating Scale (BPRS)
and positive symptoms in patients that were receiving treatment and who were heterozygous deletion carriers.10 Positive symptoms include delusions, disorganized behavior and
hallucinations, or overall "an excess or distortion of normal
function."11 Evaluation of the -141 Ins/Del SNP has not been
able to confirm association with a higher risk of developing
TD. Although the relationship is still not clearly defined,
there does appear to be an association between the SNP present at the -141 Ins/Del for the 02 dopamine receptor and
responsiveness to treatment with risperidone.

Risperidone is also an antagonist of the 03 dopamine receptor. The SNP rs6280 causes a substitution in the amino acid
sequence of serine (T allele) for glycine (C allele) in the 03
receptor. A 2005 study found that heterozygous individuals
for the C allele improved social functioning through lower
negative symptoms scores on the Positive and Negative Syndrome Scale (PANSS) and a decrease in the Nurses' Observation Scale for Inpatients Evaluation (NOSIE) while taking
risperidone.12 Negative symptoms often occur before positive symptoms and are characterized by a decline in normal
function, such as social withdrawal and a loss of interest or
emotion.11 Homozygous individuals for the T allele displayed
a less receptive response in the same tests. A second study
investigating the heterozygous genotype (C/T) yielded similar results. Patients were classified as responders or nonresponders to risperidone, and the C allele was more frequently present in responders.13 However, these results did
not reach statistical significance. This study also evaluated
the effect of the SNP rs6313 (T102C), which causes an amino
acid change to a gene that codes the SHT2A serotonin recep-

THE PHARMACY AND WELLNESS REVIEW

January 2012 Volume 3, Issue 1

Phannacogenetic Implications Regarding Second Generation Antipsychotics Oozapine and Risperidone

....,..,..,..,..,..,..,..,..,..,..,..,..,..,..,..,..,..,..,..,..,..,..,..,..,..,..,..,..,......,..,..,..,..,..,..,..,..,..,.Pharmacogenomics
tors. Patients classified as responders expressed a significantly higher proportion of C alleles than nonresponders.13 It
can therefore be inferred that risperidone treatment may not
be an efficacious choice for patients of the T/T genotype.
Polymorphisms of D3 dopamine receptors have also been
studied for their association with adverse effects in patients
receiving risperidone treatment. The Ser9--+Gly amino acid
change was shown to have an association with the risk of
developing TD. Patients, especially females, who had at least
one C allele were significantly more likely to develop limb
TD.14 A 2009 study found an association between the SNP
rs167771, which expresses either allele A or allele G on the
D3 dopamine receptor (DRD3) gene and EPS. Patients who
possessed the G allele had a higher risk of an occurrence of
EPS.7 This study has not been repeated but was conducted on
a large sample size of patients making the clinical association
more relevant.
Pharmacy Implications
Pharmacists can take a lead role in applying pharmacogenomics by judicious use of appropriate genotyping. With
genetic (SNP) information, pharmacists will be able to determine if a patient is likely to tolerate an antipsychotic, if a
patient will have significant side effects and what range of
dose a patient will require for therapeutic efficacy.
Pharmacists can utilize the new tool that is pharmacogenetic
testing to aid in selecting the appropriate medication for a
given patient to maximize therapeutic outcomes while
minimizing adverse events.
Conclusion
The current research demonstrates significant associations
between SNPs and antipsychotic drug responses/effects, but
much of the data is preliminary. All of these SNPs need to be
reevaluated in studies with larger sample sizes over longer
periods of time. Additionally, more variables need to be
included for study in order to determine the true clinical
significance of these SNPs. Single nucleotide polymorphisms
of the Dz receptors, D3 receptors, D4 receptors, and serotonin
receptors have been associated with the efficacy of clozapine
and risperidone. Cytochrome P450 SNPs have been investigated for association with TD as well as a way to predict
proper dosing for patients. Both clozapine and risperidone,
along with other antipsychotic medications, contain FDA

black box warnings. These demonstrate the significant risk of
adverse events associated with antipsychotic medication
therapy. Through additional research of SNPs and their relationship to antipsychotic medications, genetic testing of patients could help determine the efficacy and the likelihood of
adverse events of a potential medication therapy before it is
prescribed for use.
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Table 1. Significant SNPs and Patient Response to Therapy
Drug

SNP

Genomic Modification

Clozapine

rs6313

Clozapine

rs3813929

Amino acid change that causes a
variation in the SHT2A
Amino acid change that causes a
variation in the SHT2c

Risperidone

rs1799732

Amino acid change in Dz dopamine receptor

CC genotype was shown to have
a two-fold increase risk for
weight gain
Increased negative symptoms
for the deletion genotype

Risperidone

rs6313

Amino acid change that causes a
variation in the SHT2A

TT genotype less responsive to
risperidone treatment
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Effect of Modification on
Patient Response to Theraov
Poor clozapine response
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Strength ofEvidence
Confirmed through
meta-analysis
Confirmed through
meta-analysis
Association through
multiple studies. More
research needed.
Statistically significant
in two studies
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